Caroline Seymour

Treatment of renal cell carcinoma (RCC) is awaiting the potential integration of combinations of immuno-oncology agents like nivolumab (Opdivo) and ipilimumab (Yervoy), or combinations of targeted therapies with checkpoint inhibitors into the treatment paradigm. In an interview with&nbsp;<em>Targeted Oncology</em>, Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.

A novel regimen of immunotherapy, angiogenesis inhibition, and chemotherapy brings promising outcomes for patients with non-small cell lung cancer (NSCLC). The synergic combination, notes Benjamin P. Levy, MD, would be exciting to have in the landscape.

Michael A. Morse, MD, discusses a number of key trials that have broadened the treatment landscape of mCRC, the importance of toxicity management in this setting, and other ongoing developments in GI cancers.